TFRC (Transferrin Receptor 1) is a cell surface receptor that mediates cellular iron uptake through transferrin endocytosis. It plays critical roles in iron homeostasis, cellular metabolism, and has been implicated in various neurodegenerative diseases through its involvement in iron dysregulation and cellular stress responses.[1][2]
Transferrin Receptor 1 (TFRC or TfR1) is a type II transmembrane glycoprotein that facilitates the uptake of transferrin-bound iron into cells. As a key regulator of iron homeostasis, TFRC is essential for normal cellular function and viability. In the brain, TFRC is expressed on neurons, astrocytes, microglia, and endothelial cells of the blood-brain barrier, where it regulates iron entry into the central nervous system.[3]
Iron dysregulation is a hallmark of several neurodegenerative diseases, making TFRC an important therapeutic target. The receptor's role in cellular iron uptake, signal transduction, and protein metabolism provides multiple avenues for intervention in disease processes.
| Transferrin Receptor 1 | |
|---|---|
| Protein Name | Transferrin Receptor 1 |
| Gene | TFRC |
| UniProt ID | P02786 |
| PDB ID | 1CX8, 1XHA, 2HC8 |
| Molecular Weight | 190 kDa (homodimer) |
| Subcellular Location | Plasma membrane, endosomes |
| Protein Family | MHC class I family |
| Expression | Ubiquitous, highest in proliferating cells |
Transferrin Receptor 1 is a homodimeric protein, with each monomer consisting of:[4]
The receptor undergoes clathrin-mediated endocytosis and recycling through the endosomal compartment. The extracellular domain is proteolytically cleaved under certain conditions, releasing soluble TFRC (sTfR) that can be detected in blood.
TFRC is a cell surface receptor that mediates cellular iron uptake through transferrin endocytosis.[5]
Iron dysregulation is a key pathological feature of multiple neurodegenerative disorders. TFRC plays a complex role in these processes through several mechanisms:[7][8]
In Alzheimer's disease, TFRC is involved in:[9]
In Parkinson's disease, TFRC contributes to:[10]
The blood-brain barrier expresses TFRC on endothelial cells, regulating iron entry into the CNS:[12]
TFRC represents a therapeutic target for modulating brain iron homeostasis:[13]
Soluble TFRC (sTfR) in cerebrospinal fluid and blood has been studied as a biomarker:[14]
Transferrin receptor in iron homeostasis and neurodegeneration. Physiological Reviews (2015).
Brain iron metabolism and neurodegenerative disorders. Lancet Neurology (2011).
TFRC and Alzheimer's disease: Iron dysregulation and therapeutic targeting. Journal of Alzheimer's Disease (2017).
Iron and Parkinson's disease: From pathogenesis to treatment. Movement Disorders (2015).
Targeting iron dysregulation in neurodegenerative disease. Nature Reviews Neurology (2020).
The study of Tfrc Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Transferrin receptor in iron homeostasis and neurodegenerative disease. Physiological Reviews. 2015. ↩︎
Brain iron metabolism and neurodegenerative disorders. Lancet Neurology. 2011. ↩︎
Iron transport across the blood-brain barrier. Annals of the New York Academy of Sciences. 2004. ↩︎
Structure of the human transferrin receptor-transferrin complex. Nature. 2004. ↩︎
Molecular mechanism of iron uptake by transferrin. Cell. 2002. ↩︎
Transferrin receptor expression in the brain. Journal of Neuroscience Research. 1999. ↩︎
TFRC and Alzheimer's disease: Iron dysregulation and therapeutic targeting. Journal of Alzheimer's Disease. 2017. ↩︎
Iron and Parkinson's disease: From pathogenesis to treatment. Movement Disorders. 2015. ↩︎
Iron accumulation in Alzheimer's disease. Journal of Alzheimer's Disease. 2012. ↩︎
Iron in the substantia nigra of Parkinson's disease. Neurology. 2002. ↩︎
Iron dysregulation in amyotrophic lateral sclerosis. Frontiers in Aging Neuroscience. 2015. ↩︎
Blood-brain barrier transferrin receptor. Fluids and Barriers of the CNS. 2015. ↩︎
Targeting iron dysregulation in neurodegenerative disease. Nature Reviews Neurology. 2020. ↩︎
Soluble transferrin receptor in neurodegenerative diseases. Journal of the Neurological Sciences. 2013. ↩︎